Abstract:Background: Previously known as the anti-rejection drug, then famous for its efficacy on many mTOR-regulated diseases, sirolimus is now reported as the drug to reverse the process of many age-related diseases, rejuvenate immunity, and extend life span. However, its long-term safety profile for all-age groups is still a concern.Methods: Data were from two 10-year prospective cohort studies (ChiCTR-OOB-15006535,NCT031938), in which patients were diagnosed with tuberous sclerosis and/or lymphangioleiomyomatosis. Indicators on growth, hematopoietic, liver and renal function, and blood lipid were all primary outcomes. GLM analysis and Chi-square test were used to reveal their changes between the baseline and five follow-up periods (< 6 months, 6 to < 12 months, 1 to < 2 years, 2 to < 4 years, and 4-to-10 years)). Four models with cross-validation were constructed for prediction. Descriptive adverse events and the change of regimens were also recorded (secondary outcomes). Findings: 1738 patients aging from 5 days to 69 years were included. The median follow-up period was 25 (12-43) months, and 380 patients were followed for more than four years. Z scores of height, weight, and BMI increased significantly throughout the follow-up (baseline versus 4-to-10-year follow-up: 0·24 vs 0·69, 0·25 vs 0·56, 0·14 vs 0·29). The dose of sirolimus was the only factor related to all the changes. No negative effects on hematopoietic, liver, and renal function were observed throughout the follow-up. On the contrary, the long-term use of sirolimus showed beneficial effects. The increase of blood lipids was mainly in the first six months. Stomatitis was the most common adverse event (920/1738, 52·9% ), and 48·5% of adult females were with menstrual disorders. The economic burden was the main reason for discontinuing therapy.Interpretation: For the first time, we observed the increase in height and weight brought by sirolimus. Also, the length of follow-up was associated with different safety profiles. Some beneficial effects were observed in a longer follow-up.Clinical Trial Registration Details: The pediatric patients in this study are from the "Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSIPT)" study (Chinese Clinical Trial Registration, http://www.chictr.org.cn, No. ChiCTR-OOB-15006535). The adult patients re from "A National Registry on Chinese Patients with Lymphangioleiomyomatosis" (ClinicalTrials.gov, No. NCT03193892).Funding Information: This work was supported by grants from the National Key Research and Development Program of China (No. 2016YFC1000707,No.2016YFC0901502) and the National Natural Science Foundation of China (No. 81471329).Declaration of Interests: The authors have no conflicts of interest relevant tothis article to disclose.Ethics Approval Statement: The Ethics Committee of Chinese PLA General Hospital approved the pediatric study (No. S2013-028-01). The Ethics Committee of Peking Union Medical College Hospital (PUMCH) approved the adult study(JS-1323).

Case report: Effectiveness of sirolimus in a de novo FAS mutation leading to autoimmune lymphoproliferative syndrome-FAS and elevated DNT/Treg ratio

Changes in the Expression of Fas on T Lymphocytes after Allogeneic Fetal Thymus Transplantation in Systemic Lupus Erytematosus Mice.

Novel Compound Heterozygous Variants in the FAS Gene Lead to Fetal Onset of Autoimmune Lymphoproliferative Syndrome (ALPS)

Persistent High Risk HPV Infection in the Presence of a Pathogenic FAS Mutation

Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS)

Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells

RASGRP1 Mutation in Autoimmune Lymphoproliferative Syndrome-Like Disease

Safety Profile of Sirolimus in All Age Groups: A Pooled Analysis of Two 10-Year Cohort Studies Comprising 1738 Patients With Tuberous Sclerosis and/or Lymphangioleiomyomatosis

Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children's Hospital Medical Center

Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome

Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.

Revisiting double-negative T cells in autoimmune lymphoproliferative immunodeficiencies: a case series

Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study

Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study

Efficacy of Sirolimus in a 17-Month Old Patient with Primary Intestinal Lymphangiectasia

Exploratory study of autophagy inducer sirolimus for childhood cerebral adrenoleukodystrophy

Combined Therapy of Prednisone and Mtor Inhibitor Sirolimus for Treating Retroperitoneal Fibrosis

Looking for ALPS: The value of a combined assessment of biochemical markers

[Effect of Sirolimus Combined with Anti-Cd20 Monoclonal Antibody Desensitization on the Prognosis of Patients Underwent Haploidentical Stem Cell Transplantation].

Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment